Literature DB >> 17043019

Identification of risk factors in atypical chronic myeloid leukemia.

Massimo Breccia, Francesca Biondo, Roberto Latagliata, Ida Carmosino, Franco Mandelli, Giuliana Alimena.   

Abstract

In the WHO classification atypical chronic myeloid leukemia (CML) has been considered as a new distinct clinical entity included in the category of mixed myeloproliferative/myelodysplastic disorders. Little is known about this uncommon disease, whose incidence is about of one-two cases every 100 cases of Ph-positive CML. We analyzed our series of 55 patients diagnosed as having aCML, with the aim of identifying clinical factors of possible prognostic value on survival and acute transformation.

Entities:  

Mesh：

Year:  2006        PMID： 17043019

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  33 in total

1.  Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.

Authors:  Smith Giri; Ranjan Pathak; Mike G Martin; Vijaya Raj Bhatt
Journal:  Ther Adv Hematol       Date:  2015-12

2.  T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation.

Authors:  Sung-Eun Lee; Irene Jo; Woori Jang; Yonggoo Kim; Kyungja Han; Myungshin Kim
Journal:  Ann Lab Med       Date:  2015-04-01       Impact factor: 3.464

3.  Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Hui Sun; Zhifen Zhang; Xiangli Li; Yuantang Li; Li Li; Rui Xu; Zie Wang; Wenjun Tian
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

4.  Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

Authors:  Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Kaaren Reichard; Katherine P Hoversten; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-04-29       Impact factor: 10.047

Review 5.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

6.  The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT.

Authors:  S E Langabeer; S L McCarron; K Haslam; M T O'Donovan; E Conneally
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

7.  Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Authors:  Huifang Jiang; Zhonglin Wu; L I Ren; Diehong Tao; Hongyan Tong
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

8.  Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors:  Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

Review 9.  An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.

Authors:  Chetasi Talati; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 10.  The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Authors:  Jason Gotlib; Julia E Maxson; Tracy I George; Jeffrey W Tyner
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.